Novavax begins phase 3 trial of flu vaccine candidate

A Gaithersburg biotechnology company is beginning a clinical trial which the FDA can examine when determining whether to approve its influenza vaccine.

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *